To study the possible correlation between galectin-3 expression and the malignant potential in primary melanoma lesions they conducted an immunohistochemical study with monoclonal anti-galectin-3 antibody in a series of primary and metastatic melanoma lesions as well as benign skin pigmented lesions. The gene discussed is LGALS3; the disease is melanoma.